Viz.ai announced Wednesday, March 17, that the company has raised $71 million in Series C funding to expand the use of its AI platform—most commonly used to treat stroke patients—so that it can have a greater impact in cardiology and other specialties.
“This latest round of funding validates the potential of Viz.ai’s technology, both in and beyond stroke care coordination,” Chris Mansi, co-founder and CEO of Viz.ai, said in a prepared statement. “The investment will allow us to expedite our effort to bring the power of artificial intelligence and advanced mobile technology to prevent care breakdowns, improve patient outcomes and experience, and improve economics across the entire health system both in the United States and Europe.”
The new funding is expected to help Viz.ai ramp up the use of its AI technology in such areas as cardiology, pulmonary care and trauma care. Scale Venture Partners and Insight Partners led the funding round. Greenoaks, Kleiner Perkins, Threshold Ventures, CRV, Innovation Endeavors and Susa Ventures all provided additional resources.
“Viz.ai has taken an innovative approach to transforming one of healthcare’s biggest challenges, using intuitive technology to help improve patient outcomes in acute care,” Nikhil Sachdev, managing director of Insight Partners, said in the same statement. “We see the company poised for massive growth as it scales its clinically-verified stroke care coordination system to other use cases where time is crucial to outcomes and costs to patients and hospitals can exponentially increase when care coordination breaks down. We are looking forward to rolling up our sleeves and helping Viz.ai scale up.”